| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| BIIB | Biogen Inc. | $334.44 | $67.37B | Sell |
3 High-Quality Biotech Companies for 4th Quarter
http://www.gurufocus.com/news/740841/3-highquality-biotech-companies-for-4th-quarter
Sep 17, 2018 - 3 High-Quality Biotech Companies for 4th Quarter, Stocks: BIIB,GILD,NVO,BRK.A,BRK.B,AMGN,CELG, Warren Buffett, release date:Sep 17, 2018
0
Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo
http://www.zacks.com/stock/news/322511/alkermes-expands-study-to-evaluate-alks-4230-keytruda-combo?cid=CS-ZC-FT-322511
Sep 11, 2018 - Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.
0
Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
http://www.zacks.com/stock/news/322477/acorda-gets-unfavorable-court-ruling-for-ampyra-stock-down?cid=CS-ZC-FT-322477
Sep 11, 2018 - Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra
0
Small Caps Are Rising, Biotechs Can't Be Far Behind
https://seekingalpha.com/article/4204248-small-caps-rising-biotechs-far-behind?source=feed_tag_etf_portfolio_strategy
Sep 05, 2018 - While much attention is being riveted on the S&P 500's new all-time high eclipsing the January one, small caps accomplished that in May.Small caps are in their next leg up as they record new all-time
0
Biogen Begins Phase III Study on Ischemic Stroke Candidate
http://www.zacks.com/stock/news/321608/biogen-begins-phase-iii-study-on-ischemic-stroke-candidate?cid=CS-ZC-FT-321608
Sep 05, 2018 - Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
0
Lilly (LLY) Hits 52-Week High, Can the Run Continue?
http://www.zacks.com/stock/news/318540/lilly-lly-hits-52-week-high-can-the-run-continue?cid=CS-ZC-FT-318540
Aug 17, 2018 - Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
0
Why Biogen's Stock Ripped Higher in July
https://www.fool.com/investing/2018/08/11/why-biogens-stock-ripped-higher-in-july.aspx?source=iedfolrf0000001
Aug 11, 2018 - Biogen's stock got a boost from two material events last month.
0
Country Trust Bank Buys Incyte Corp, First Trust Preferred Securities and Income ETF, Visa Inc, ...
http://www.gurufocus.com/news/721728/country-trust-bank-buys-incyte-corp-first-trust-preferred-securities-and-income-etf-visa-inc-sells-bristolmyers-squibb-company-monsanto-co-cardinal-health-inc
Aug 10, 2018 - Country Trust Bank Buys Incyte Corp, First Trust Preferred Securities and Income ETF, Visa Inc, Sells Bristol-Myers Squibb Company, Monsanto Co, Cardinal Health Inc, Stocks: V,XLY,NVS,BIIB,AWK,EW,INCY,FPE,JEC,BND,LOW,MUSA,MO, release date:Aug 10, 2018
0
Are Drug Stocks Starved Of Capital?
https://seekingalpha.com/article/4197786-drug-stocks-starved-capital?source=feed_tag_etf_portfolio_strategy
Aug 10, 2018 - The prevailing narrative is that drug stocks are not investible because drug pricing is at risk of collapsing.We see drug spending becoming less, not more, of an issue.From such current valuation leve
0
Biotech ETFs in Focus on String of Q2 Earnings Beat
http://www.zacks.com/stock/news/317516/biotech-etfs-in-focus-on-string-of-q2-earnings-beat?cid=CS-ZC-FT-317516
Aug 10, 2018 - Biotech ETFs draw attention post impressive Q2 results.
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| GILD | Gilead Sciences, Inc. | NASDAQ | $72.78 | $94.35B |
| SGEN | Seattle Genetics, Inc. | NASDAQ | $76.15 | $12.09B |
| NBIX | Neurocrine Biosciences, Inc. | NASDAQ | $117.38 | $10.62B |
| QGEN | Qiagen N.V. | NASDAQ | $37.42 | $8.5B |
| QGEN | Qiagen N.V. | NYSE | $37.42 | $8.5B |